Fractyl Health (NASDAQ:GUTS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference
Fractyl Health (NASDAQ:GUTS) had its price target raised by analysts at Canaccord Genuity Group Inc. from $6.00 to $8.00. They now have a "buy" rating on the stock.
Fractyl Health outlines 2026 Revita pivotal data and PMA submission targets as clinical momentum accelerates [Seeking Alpha]